MITSUBISHI TANABE PHARMA CORPORATION;JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY OF NATIONAL INSTITUTE OF INFECTIOUS DESEASES
发明人:
申请号：
EP01904385.0
公开号：
EP1256348B1
申请日:
2001.02.13
申请国别(地区):
EP
年份:
2012
代理人:
摘要：
The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.L'invention concerne une substance qui inhibe la fixation de la protéine E2/NS1 du virus de l'hépatite C à des cellules à infectiosité potentielle par ledit virus et à des cellules exprimant CD81. Elle concerne également des médicaments ayant une action antivirale (inhibition de l'infection à VHC, etc.).
